Tacrolimus (FK506) in Thoracic Organ Transplantation

  • J. S. Gammie
  • S. M. Pham


Tacrolimus (FK506) was discovered as the result of a systematic screening program to look for an improved immunosuppressant. In the mid-1980s Goto and associates from the Exploratory Research Laboratories of Fujisawa Pharmaceutical Co. Ltd, Japan, discovered a macrolide compound that had potent immunosuppressive properties[1]–[3]. This compound, then named FK506, was extracted from the fermentation broth of the soil fungus Streptomyces tsukubaensis. Further preclinical studies on the immunosuppressive properties of this compound on organ transplantation were carved out intensively at Chiba University, Japan[4]–[9], Cambridge University, UK[10]–[12], and the University of Pittsburgh, USA[13]–[18]. The initial results of FK506 as an effective immunosuppressant in organ transplantation were presented at the first International Symposium on FK506 in June 1987, in Gëteborg, Sweden, and were subsequently published in Transplantation Proceedings (Vol. 19, Suppl. 6, 1987).


Acute Rejection Transplant Proc Liver Transplant Recipient Obliterative Bronchiolitis Tacrolimus Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Goto T, Kino T, Hatanaka H et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc. 1987; 19(Suppl.6):4–8.PubMedGoogle Scholar
  2. 2.
    Kino T, Hatanaka H, Miyata S et al. FK-506, a novel immunosuppressant isolated from a streptomyces. I. Fermentation, isolation and physicochemical and biological characteristics. J Antibiot (Tokyo). 1987;40:1249–55.Google Scholar
  3. 3.
    Kino T, Hatanaka H, Miyata S et al. FK-506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Anlibiol (Tokyo). 1987;40:1256–65.Google Scholar
  4. 4.
    Ochiai T, Nakajima K, Nagata M et al. New immunosuppressive drugs: effect of a new immunosuppressive agent, FK506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc. 1987;19:1284–6.PubMedGoogle Scholar
  5. 5.
    Ochiai T, Nakajima K, Nagata M et al. Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation. 1987;44:734–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Ochiai T, Nagata M, Nakajima K et al. Studies of the effects of FK 506 on renal allograft in the beagle dog. Transplantation. 1987;44:729–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Ochiai T, Hamaguchi K, Isono K. Histopathologic studies in renal transplant recipient dogs receiving treatment with FK 506. Transplant Proc. 1987;19(Suppl. 6):93–7.PubMedGoogle Scholar
  8. 8.
    Ochiai T, Sakamoto K, Gunji Y et al. Effects of combination treatment with FK 506 and cyclosporine on survival time and vascular changes in renal allograft recipient dogs. Transplantation. 1989;48:193–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Ochiai T, Gunji Y, Sakamoto K el al. Optimal serum trough levels of FK 506 in renal allotransplantation of the beagle dog. Transplantation. 1989;48:189–93.PubMedCrossRefGoogle Scholar
  10. 10.
    Lim SML, Thiru S, While DJG. Heterotopic heart transplantation in the rat receiving FK 506. Transplant Proc. 1987; 19:68–70.PubMedGoogle Scholar
  11. 11.
    Collier DS, Thiru S, Calne R. Kidney transplantation in the dog receiving FK506. Transplant Proc. 1987;19(Suppl. 6):62.PubMedGoogle Scholar
  12. 12.
    Thiru S, Collier DS, Calne R. Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK 506. Transplant Proc. 1987; 19(Suppl. 6):98–9.PubMedGoogle Scholar
  13. 13.
    Murase N, Todo S, Lee P-H et al. Heterotopic heart transplantation in the rat under FK506 alone or with cyclosporine. Transplant Proc. 1987;19(Suppl. 6):57–61.Google Scholar
  14. 14.
    Todo S, Demetris AJ, Ueda Y et al. Canine kidney transplantation with FK 506 alone or in combination with cyclosporine and steroids. Transplant Proc. 1987;19(Suppl.6):57–61.PubMedGoogle Scholar
  15. 15.
    Todo S, Ueda Y, Demetris AJ et al. Immunosuppression of canine, monkey, and baboon allografts by FK506 with special reference to synergism with other drugs and tolerance induction. Surgery. 1988;104:239–40.PubMedGoogle Scholar
  16. 16.
    Todo S, Demetris A, Ueda Y et al. Renal transplantation in baboon under FK 506. Surgery. 1989;106:444–51.PubMedGoogle Scholar
  17. 17.
    Zeevi, Duquesnoy RJ, Eiras G et al. Immunosuppressive effect of FR-900506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc. 1987;19(Suppl. 6):40–4.PubMedGoogle Scholar
  18. 18.
    Warty V, Diven W, Cadoff E et al. FK506: a novel immunosuppressive agent: characteristics of binding and uptake by human lymphocytes. Transplantation. 1988;46:453–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Starzl TE, Todo S, Fung J et al. FK506 for human liver, kidney and pancreas transplantation. Lancet. 1989;2:1000–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Todo S, Fung JJ, Starzl TE et al. Liver, kidney, and thoracic organ transplantation under FK506. Ann Surg. 1990;212:295–305.PubMedCrossRefGoogle Scholar
  21. 21.
    Starzl TE, Fung J, Jordan M et al. Kidney transplantation under FK506. J Am Med Assoc. 1990;264:63–7.CrossRefGoogle Scholar
  22. 22.
    Armitage JM, Flicker FJ, del Nido P, Cipriani L, Starzl TE. The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. Transplant Proc. 1991;23:3058–60.PubMedGoogle Scholar
  23. 23.
    Armitage JM, Kormos RL, Fung J, Starzl TE. The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc. 1991;23:3054–7.PubMedGoogle Scholar
  24. 24.
    Fung J, Abu-Elmagd K, Jain A et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc. 1991;23:2977–83.PubMedGoogle Scholar
  25. 25.
    Japanese FK 506 Study Group: Clinicopathological evaluation of kidney transplants in patients given a fixed dose of FK 506. Transplant Proc. 1991;23:3111–15.Google Scholar
  26. 26.
    U.S. Multicenter FK 506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 1994;331:1110–15.CrossRefGoogle Scholar
  27. 27.
    European FK 506 Multicenter Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet. 1994;344:423–8.CrossRefGoogle Scholar
  28. 28.
    Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science. 1991;251:283–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Liu J, Farmer JD Jr., Lane WS et al. Calcineurin is a common target of cyclosporine A and FKBP-FK506 complexes. Cell. 1991;66:807–15.PubMedCrossRefGoogle Scholar
  30. 30.
    Schreiber SL, Liu J, Albers MW et al. Immunophilin-ligand complexes as probes of intracellular signalling pathways. Transplant Proc. 1991:23:2839–44.PubMedGoogle Scholar
  31. 31.
    Sigal NH, Dumont FJ, Cyclosporine A, FK 506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol. 1992;10:519–60.PubMedGoogle Scholar
  32. 32.
    Morris R. Modes of action of FK506, cyclosporine A, and rapamycin. Transplant Proc. 1994;26:3272–5.PubMedGoogle Scholar
  33. 33.
    Flanagan WF, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporine A. Nature. 1991;352:803–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Venkataramanan R, Jain A, Warty VS et al. Pharmacokinetics of FK 506 in transplant patients. Transplant Proc. 1991;23:2736–40.PubMedGoogle Scholar
  35. 35.
    Sewing KF. Pharmacokinetics, dosing principles, and blood level monitoring of FK506. Transplant Proc. 1994;26:3267–9.PubMedGoogle Scholar
  36. 36.
    Todo S, Fung JJ, Tzakis A et al. One hundred and ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc. 1991;23:1397–402.PubMedGoogle Scholar
  37. 37.
    Tamaura K, Kobayashi M, Hashimoto K et al. A highly sensitive method to assay FK506 levels in plasma. Transplant Proc. 1987;19:23.Google Scholar
  38. 38.
    Grenier FC, Luczkiw J, Bergmann M et al. A whole blood FK506 assay for the IMx analyzer. Transplant Proc. 1991;23:2748–9.PubMedGoogle Scholar
  39. 39.
    Abu-Elmagd KM, Fung J, Draviam R et al. Four hour versus 24 hour intravenous infusion of FK 506 in liver transplantation. Transplant Proc. 1991;23:2767–70.PubMedGoogle Scholar
  40. 40.
    Griffith BP, Bando K, Hardesty RL et al. A prospective randomized trial of FK 506 versus cyclosporine after human pulmonary transplantation. Transplantation. 1994;57:848–51.PubMedCrossRefGoogle Scholar
  41. 41.
    Jain AB, Fung J, Todo S el al. One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. Transplant Proc. 1995;27:1099–1104.PubMedGoogle Scholar
  42. 42.
    U.S. Multicenter Liver Study Group. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from U.S. Multicenter Trial. Transplant Proc. 1995;27:1114–16.Google Scholar
  43. 43.
    Eidelman BH, Abu-Elmagd K, Wilson J et al. Neurological complications of FK506. Transplant Proc. 1991;23:3175–8.PubMedGoogle Scholar
  44. 44.
    Reyes J, Gayowski T, Fung J et al. Expressive dysphagia possibly related to FK506 in two liver transplant recipients. Transplantation. 1990;50:1043–5.PubMedCrossRefGoogle Scholar
  45. 45.
    U.S. Multicentcr FK 506 Liver Study Group. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. Transplant Proc. 1993;25:679–88.Google Scholar
  46. 46.
    Annitage JM, Fricker FJ, del Nido P et al. A decade (1982–1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression. J Thorac Cardiovasc Surg. 1993;105:464–72.Google Scholar
  47. 47.
    Armitage JM, Kormos RL, Morita S et al. Clinical trial of FK 506 immuno-suppression in adult cardiac transplantation. Ann Thorac Surg. 1992;54:205–10.PubMedCrossRefGoogle Scholar
  48. 48.
    Pham SM, Kormos RL, Hattler BG. A prospective trial of tacrolimus (FK506) in clinical heart transplantation: intermediate term results. J Thorac Cardiovasc Surg. 1996;111(4):764–72.PubMedCrossRefGoogle Scholar
  49. 49.
    Bolman RM, Elick B, Olivari MT, Ring WS, Arentzen CE. Improved immunosuppression for cardiac transplantation. J Heart Transplant. 1985;4:315–18.PubMedGoogle Scholar
  50. 50.
    Keenan RJ, Konishi H, Paradis I et al. A clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg. 1995;60.580–5.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • J. S. Gammie
  • S. M. Pham

There are no affiliations available

Personalised recommendations